Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
72.5
217.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Other Long-Term Assets
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Long-Term Assets
¥304.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Other Long-Term Assets
¥363.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Other Long-Term Assets
¥405.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Other Long-Term Assets
¥1.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
32%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Other Long-Term Assets
¥81.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View
Nestled in the vibrant economic landscape of China, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. emerges as a prominent figure within the biopharmaceutical industry. Founded as a subsidiary of the larger pharmaceutical umbrella of Sichuan Kelun Pharmaceutical Co., Ltd., the company leverages its parent's extensive network and expertise to carve its niche in an ever-evolving market. Kelun-Biotech focuses on innovation in drug development, particularly in biologics and complex generics. This focus allows it to produce high-value pharmaceuticals that address urgent medical needs, spanning across treatments for oncology, immunological disorders, and other critical health segments. Its dedication to cutting-edge research and development is evident in the substantial investments it channels into its laboratories and collaborations with leading research institutions, both domestically and internationally. The company's revenue model pivots around the commercialization of its proprietary drugs and partnerships with multinational pharmaceutical firms, where it contributes its research prowess to joint ventures. By positioning itself as a leader in the biologics sector, Kelun-Biotech capitalizes on the growing demand for biosimilars and innovative therapies in the global market. Its strategy to penetrate international markets is further bolstered by strategic alliances and compliance with stringent global regulatory approvals, enhancing its credibility and reach. These endeavors not only drive its revenue growth but also reinforce its mission to deliver high-quality, affordable healthcare solutions worldwide, making Kelun-Biotech an influential player in addressing global health challenges through pharmaceutical excellence.
You don't have any saved screeners yet
